These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 30499777)

  • 21. Treatment of chronic daily headache with comorbid anxiety and depression using botulinum toxin A: a prospective pilot study.
    Zhang H; Zhang H; Wei Y; Lian Y; Chen Y; Zheng Y
    Int J Neurosci; 2017 Apr; 127(4):285-290. PubMed ID: 27439999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical features of new daily persistent headache: A retrospective chart review of 328 cases.
    Evans RW; Turner DP
    Headache; 2021 Nov; 61(10):1529-1538. PubMed ID: 34710236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The classification of chronic daily headache in adolescents--a comparison between the second edition of the international classification of headache disorders and alternative diagnostic criteria.
    Bigal ME; Rapoport AM; Tepper SJ; Sheftell FD; Lipton RB
    Headache; 2005 May; 45(5):582-9. PubMed ID: 15953277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
    Negro A; Curto M; Lionetto L; Martelletti P
    J Headache Pain; 2015; 17():1. PubMed ID: 26792662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ketamine Infusions for Treatment Refractory Headache.
    Pomeroy JL; Marmura MJ; Nahas SJ; Viscusi ER
    Headache; 2017 Feb; 57(2):276-282. PubMed ID: 28025837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Features and Management of New Daily Persistent Headache in Developmental-Age Patients.
    Papetti L; Sforza G; Tarantino S; Moavero R; Ruscitto C; Ursitti F; Ferilli MAN; Vigevano F; Valeriani M
    Diagnostics (Basel); 2021 Feb; 11(3):. PubMed ID: 33668316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New Daily Persistent Headache in a Pediatric Population.
    Strong E; Pierce EL; Langdon R; Strelzik J; McClintock W; Cameron M; Furda M; DiSabella M
    J Child Neurol; 2021 Sep; 36(10):888-893. PubMed ID: 34048280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Primary new daily persistent headache (NDPH): clinical characteristics of forty-three cases in Japan].
    Takase Y; Nakano M; Tatsumi C
    Rinsho Shinkeigaku; 2003 Sep; 43(9):533-8. PubMed ID: 14727558
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison and predictors of chronic migraine vs. new daily persistent headache presenting with a chronic migraine phenotype.
    Nagaraj K; Wei DY; Puledda F; Weng HY; Waheed S; Vandenbussche N; Ong JJY; Goadsby PJ
    Headache; 2022 Jul; 62(7):828-838. PubMed ID: 35861031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Refractory Headaches.
    Begasse de Dhaem O; Rizzoli P
    Semin Neurol; 2022 Aug; 42(4):512-522. PubMed ID: 36323303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New daily persistent headache.
    Evans RW
    Curr Pain Headache Rep; 2003 Aug; 7(4):303-7. PubMed ID: 12828880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Headache trajectories in children and adolescents with new onset continuous headache.
    Szperka CL; Evans M; Patterson Gentile C; Panigrahi P; Raj NR; Marquez de Prado B; Hershey AD; Gelfand AA
    Cephalalgia; 2024 Oct; 44(10):3331024241282803. PubMed ID: 39370854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.
    Guerzoni S; Pellesi L; Baraldi C; Pini LA
    J Headache Pain; 2015; 17():48. PubMed ID: 27146068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychiatric comorbidity in new daily persistent headache: A cross-sectional study.
    Uniyal R; Paliwal VK; Tripathi A
    Eur J Pain; 2017 Jul; 21(6):1031-1038. PubMed ID: 28146324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features, effectiveness of drug-based treatment, and prognosis of new daily persistent headache (NDPH): 30 cases in Japan.
    Takase Y; Nakano M; Tatsumi C; Matsuyama T
    Cephalalgia; 2004 Nov; 24(11):955-9. PubMed ID: 15482358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
    Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
    Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New daily persistent headache: An evolving entity.
    Uniyal R; Paliwal VK; Anand S; Ambesh P
    Neurol India; 2018; 66(3):679-687. PubMed ID: 29766926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example.
    Dodick DW; Turkel CC; DeGryse RE; Diener HC; Lipton RB; Aurora SK; Nolan ME; Silberstein SD
    J Pain; 2015 Feb; 16(2):164-75. PubMed ID: 25464159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New daily persistent headache in children and adolescents.
    Baron EP; Rothner AD
    Curr Neurol Neurosci Rep; 2010 Mar; 10(2):127-32. PubMed ID: 20425237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
    Dowson AJ; Kilminster SG; Salt R
    Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.